BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saiman L. Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy. Pediatr Pulmonol 2019;54 Suppl 3:S18-26. [PMID: 31715086 DOI: 10.1002/ppul.24522] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Saluzzo F, Riberi L, Messore B, Loré NI, Esposito I, Bignamini E, De Rose V. CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis. Cells 2022;11:1243. [DOI: 10.3390/cells11071243] [Reference Citation Analysis]
2 Knoppers T, Cosquer M, Hagan J, Nguyen MT, Knoppers BM. “The Stakes Are Higher”- Patient and Caregiver Perspectives on Cystic Fibrosis Research and Personalized Medicine. Front Med 2022;9:841887. [DOI: 10.3389/fmed.2022.841887] [Reference Citation Analysis]
3 Ferrera L, Cappiello F, Loffredo MR, Puglisi E, Casciaro B, Botta B, Galietta LJV, Mori M, Mangoni ML. Esc peptides as novel potentiators of defective cystic fibrosis transmembrane conductance regulator: an unprecedented property of antimicrobial peptides. Cell Mol Life Sci 2021. [PMID: 34971429 DOI: 10.1007/s00018-021-04030-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Durfey SL, Pipavath S, Li A, Vo AT, Ratjen A, Carter S, Morgan SJ, Radey MC, Grogan B, Salipante SJ, Welsh MJ, Stoltz DA, Goss CH, McKone EF, Singh PK. Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections. mBio 2021;12:e0314821. [PMID: 34903059 DOI: 10.1128/mbio.03148-21] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
5 Holliday ZM, Launspach JL, Durairaj L, Singh PK, Zabner J, Stoltz DA. Effects of Tham Nasal Alkalinization on Airway Microbial Communities: A Pilot Study in Non-CF and CF Adults. Ann Otol Rhinol Laryngol 2021;:34894211051814. [PMID: 34674574 DOI: 10.1177/00034894211051814] [Reference Citation Analysis]
6 Gur M, Bar-Yoseph R, Toukan Y, Hanna M, Masarweh K, Bentur L. Twelve years of progressive Mycobacterium abscessus lung disease in CF-Response to Trikafta. Pediatr Pulmonol 2021;56:4048-50. [PMID: 34432957 DOI: 10.1002/ppul.25637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Woods DF, Flynn S, Caparrós-Martín JA, Stick SM, Reen FJ, O'Gara F. Systems Biology and Bile Acid Signalling in Microbiome-Host Interactions in the Cystic Fibrosis Lung. Antibiotics (Basel) 2021;10:766. [PMID: 34202495 DOI: 10.3390/antibiotics10070766] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Shemie G, Nguyen MT, Wallenburg J, Ratjen F, Knoppers BM. The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada. J Pers Med 2021;11:382. [PMID: 34067090 DOI: 10.3390/jpm11050382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yi B, Dalpke AH, Boutin S. Changes in the Cystic Fibrosis Airway Microbiome in Response to CFTR Modulator Therapy. Front Cell Infect Microbiol 2021;11:548613. [PMID: 33816324 DOI: 10.3389/fcimb.2021.548613] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 17.0] [Reference Citation Analysis]
10 Martin I, Waters V, Grasemann H. Approaches to Targeting Bacterial Biofilms in Cystic Fibrosis Airways. Int J Mol Sci 2021;22:2155. [PMID: 33671516 DOI: 10.3390/ijms22042155] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
11 Kolbin AS, Gomon YM, Karpov OI, Balykina YE, Proskurin MA. Cystic fibrosis as a social-economic burden. GCP 2021. [DOI: 10.37489/2588-0519-2020-5-38-49] [Reference Citation Analysis]
12 Cuevas-Ocaña S, Laselva O, Avolio J, Nenna R. The era of CFTR modulators: improvements made and remaining challenges. Breathe (Sheff) 2020;16:200016. [PMID: 33304402 DOI: 10.1183/20734735.0016-2020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
13 Orsini E, Miranda C, Dasenbrook E. Antibiotic Use and Stewardship in Cystic Fibrosis: A Review for Noncystic Fibrosis Providers. Clinical Pulmonary Medicine 2020;27:131-8. [DOI: 10.1097/cpm.0000000000000370] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Asseri AA. Cystic fibrosis knowledge and practice among primary care physicians in southwest region, Saudi Arabia. J Family Med Prim Care 2020;9:1354-61. [PMID: 32509615 DOI: 10.4103/jfmpc.jfmpc_1168_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]